Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
The Motley Fool June 4, 2008 Brian Lawler	Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares.
The Motley Fool September 13, 2007 Brian Lawler	ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
Registered Rep. February 1, 2005 Bob Hirschfeld	Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool September 11, 2006 Brian Lawler	More Work on Cancer Drug for Genentech The FDA asks for more data about Avastin, which could be used to treat various cancers. Investors, take note.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
The Motley Fool May 5, 2005 Charly Travers	OSI's Cancer Blockbuster Tarceva will turn OSI Pharmaceuticals into a leading biotech.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool December 3, 2004 W.D. Crotty	One Hot Biotech Stock Biomira reports favorable Phase II test results, sending the stock up 146%.
The Motley Fool April 8, 2004 Brian Gorman	Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
The Motley Fool November 19, 2004 Charly Travers	A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
The Motley Fool December 20, 2004 Charly Travers	More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool April 27, 2004 Alyce Lomax	Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool August 27, 2007 Brian Lawler	Round 2 for Genentech Learn a lesson or two from Genentech's's dance with the FDA. The drugmaker's experience serves as a reminder of the fickle nature of the government agency, and the sometimes frustrating process of bringing a medication to market.
The Motley Fool April 29, 2005 Tim Hanson	Genentech's Promising Future Cancer drug Avastin is finding new uses. How will outside forces affect its potential? Investors take note.
The Motley Fool June 12, 2007 Brian Lawler	ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label.
BusinessWeek October 6, 2003 Arlene Weintraub	Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science."
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool November 21, 2008 Brian Orelli	Coughing Is Bad for Amgen's Health Safety concerns halt drug trial, but all is not lost.
The Motley Fool February 25, 2008 Brian Lawler	A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer.
The Motley Fool January 5, 2005 Charly Travers	AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool July 8, 2004 Charly Travers	Genentech's Next Billion-Dollar Drug The cancer drug Avastin looks like a big winner. The market had exceptionally high expectations for this product, and it certainly seems well on its way to becoming a blockbuster drug.
The Motley Fool July 12, 2006 Stephen D. Simpson	Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered.
The Motley Fool September 14, 2009 Brian Orelli	More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer.
The Motley Fool May 7, 2008 Brian Orelli	Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year.
The Motley Fool November 21, 2008 Brian Orelli	The Comeback of the Century? AstraZeneca is trying to revive Iressa.
The Motley Fool December 4, 2007 Brian Lawler	Will Avastin Squeeze Past the FDA? Unless an FDA advisory panel provides extremely strong reasoning for approving Avastin on the evidence of PFS benefits alone, Genentech and its investors should expect another approvable letter come January.
The Motley Fool December 6, 2007 Brian Lawler	Genentech Voted Down An FDA panel recommends against expanded use of Genentech's lead drug.
BusinessWeek July 31, 2006 Gene G. Marcial	Genentech Is More Robust Than It Looks Genentech, the world's second-largest biotech and an innovative developer of biotherapeutics, gets no favors from the Street.
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
The Motley Fool February 21, 2008 Brian Orelli	Onyx's Double Dose of Trouble Poor clinical trial data and a lack of profits hit the drugmaker hard. Investors, take note.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
The Motley Fool November 17, 2008 Brian Orelli	The Little Chemotherapy That Could Abraxis BioScience has a lot of potential, but, in this market, the company is going to have to show investors that it can make it over the hill before they're going to jump on board.
The Motley Fool September 28, 2010 Brian Orelli	Pfizer's Sutent Fails. Again! No surprise here.
The Motley Fool January 15, 2008 Brian Lawler	Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool July 15, 2008 Brian Orelli	Will a New Use Help Schering-Plough's Near-Blockbuster Drug? Delaying relapses probably won't be enough to get its Pegintron approved as a treatment for melanoma.
The Motley Fool May 2, 2011 Tim Beyers	Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment.